Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723190 · ClinicalTrials.gov registry record · Phase 3
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 303
- Enrollment target
NCT00723190 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 303 participants.
The verdict
NCT00723190, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attention deficit hyperactivity disorder (ADHD).
Interventions
- DRUG CLONICEL (Clonidine HCl sustained release)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00723190
The ClinicalTrials.gov registry entry for NCT00723190 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CLONICEL (Clonidine HCl sustained release) is the first listed.
NCT00723190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00723190 about?
NCT00723190 is a clinical study titled "Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)". The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attenti...
What is the current status of trial NCT00723190?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 303 participants. The study started on 2008-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00723190?
The interventions under investigation include: CLONICEL (Clonidine HCl sustained release) (DRUG).
Who is sponsoring clinical trial NCT00723190?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.